An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease
- 1 September 2001
- journal article
- clinical trial
- Published by Elsevier in Kidney International
- Vol. 60 (3), 1106-1113
- https://doi.org/10.1046/j.1523-1755.2001.0600031106.x
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patientsKidney International, 2000
- Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal diseaseAmerican Journal of Kidney Diseases, 1999
- Hyperhomocysteinemia in high-aged subjects: relation of B-vitamins, folic acid, renal function and the methylenetetrahydrofolate reductase mutationAtherosclerosis, 1999
- MTHFR association with arteriosclerotic vascular disease?Human Genetics, 1998
- The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemiaQJM: An International Journal of Medicine, 1996
- Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patientsAtherosclerosis, 1996
- Folic acid, pyridoxine, cobalamin, and homocysteine and their relationship to cardiovascular disease in end-stage renal diseaseJournal of Renal Nutrition, 1996
- Diabetic Nephropathy and End-Stage Renal Disease in Mexican AmericansBlood Purification, 1996
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control studyAtherosclerosis, 1995